Kymera Therapeutics, Inc. (KYMR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Watertown, MA, 미국. 현재 CEO는 Nello Mainolfi.
KYMR 을(를) 보유 IPO 날짜 2020-08-21, 208 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $7.34B.
Kymera Therapeutics, Inc. is a biopharmaceutical company founded in 2015 and based in Watertown, Massachusetts that specializes in discovering and developing small molecule therapeutics designed to selectively degrade disease-causing proteins using the body's natural protein degradation system. The company's pipeline includes the IRAK4 program currently in Phase I clinical trials for immunology and inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; the IRAKIMiD program targeting MYD88-mutated diffuse large B cell lymphoma; the STAT3 program for treating hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis; and the MDM2 program for hematological and solid tumors. Through its proprietary protein degradation platform, Kymera aims to address significant unmet medical needs across oncology, immunology, and other therapeutic areas.
